Novartis

History

Novartis was created in 1996 from the merger of Ciba-Geigy and Sandoz Laboratories, both Swiss companies with long histories. At the time it was said to be the largest corporate merger in history. Ciba-Geigy was formed in 1970 by the merger of J. R. Geigy (founded in Basel in 1758) and Ciba (founded in Basel in 1859). Considering the histories of the merger partners, the company's history spans almost 250 years.^[2]

Ciba-Geigy

Johann Rudolf Geigy-Gemuseus (1733 – 1793) began trading in 1758 in "materials, chemicals, dyes and drugs of all kinds" in Basel, Switzerland. Johann Rudolf Geigy-Merian (1830 – 1917) and Johann Muller-Pack acquire a site in Basel in 1857, where they build a fuchsine. In 1901 Geigy is transformed into a public limited company and in 1914, the name of the company is changed to J.R. Geigy Ltd.

In 1859 Alexander Clavel (1805 – 1873) takes up the production of fuchsine in his factory for silk dyeing works in Basel. In 1864, a new site for the production of synthetic dyes is constructed, and in 1873, Clavel sells his dye factory to the new company Bindschedler & Busch. In 1884 Bindschedler & Busch is transformed into a joint-stock company with the name "Gesellschaft für Chemische Industrie Basel" (Company for Chemical Industry Basel). The abbreviation CIBA becomes so widespread that it was adopted as the company's name in 1945.

In 1925 J.R. Geigy Ltd. starts producing textile auxiliaries, an activity which Ciba takes up in 1928.

Ciba and Geigy merged in 1971 to form Ciba‑Geigy Ltd., and this company merged with Sandoz in 1996 to form Novartis.

Sandoz

Sandoz is perhaps best known for synthesizing antipyrin in the same year.

Between the World Wars, Gynergen (1921) and Calcium-Sandoz (1929) were brought to market. Sandoz also produced chemicals for textiles, paper, and leather beginning in 1929. In 1939, they began producing agricultural chemicals.

From 1899, the sugar substitute Ciba-Geigy to form Novartis in 1996, Sandoz also engaged in drug development. Pharmaceutical research began in 1917 under Professor Arthur Stoll (1887-1971). In 2005, Sandoz expanded significantly though the acquisition of Hexal, one of Germany’s leading generics company, and Eon Labs, a fast-growing U.S. generic pharmaceutical company.

The psychotomimetic" because they were thought to mimic psychosis. Later research caused this term to be abandoned, as neuroscientists gained a better understanding of psychoses, including schizophrenia. Research on LSD peaked in the 1950s and early 1960s. Sandoz withdrew the drug from the market in the mid 1960s.

Sandoz opened its first foreign offices in 1964.

In 1967, Sandoz merged with Wander AG (known for Ovomaltine and Isostar). Sandoz acquired the companies Delmark, Wasabröd (Swedish manufacturer of crisp bread), and Gerber Products Company baby food makers.

On November 1, 1986, a fire broke out in a production plant storage room, which led to a large amount of pesticide being released into the upper Rhine. This exposure killed many fish.

In 1995, Sandoz spun off its speciality chemicals business to form Hoechst in Germany.

After the merger

After the merger, Novartis reorganized its activities, and spun out its chemicals activities as Ciba Specialty Chemicals.

In 1998 the company made headlines with its biotechnology licensing agreement with the UC Berkeley Department of Plant and Microbial Biology. Critics of the agreement expressed concern over prospects that the agreement would diminish academic objectivity, or lead to the commercialization of genetically modified plants. The agreement expired in 2003.

Novartis combined its agricultural division with that of Syngenta in November 2000.

In 2003, Novartis created generic drug production, reusing the brand of one of its predecessor companies.

On April 20 2006 Novartis acquired the California-based Chiron Corporation. Chiron was formerly divided into three units: Chiron Vaccines and Chiron Blood Testing, which now combine to form Novartis Vaccines and Diagnostics, and Chiron BioPharmaceuticals, to be integrated into Novartis Pharmaceuticals.

The ongoing Basel Campus Project has the aim to transform the St. Johann site - Novartis headquarters in Basel - "from an industrial complex to a place of innovation, knowledge and encounter". ^[4]

On 2005, Novartis introduced Certican® (Everolimus), an immunosuppressant. Everolimus is also Novartis' first marketed immunosupressant, after the approval of cyclosporin A.

On October 2006, Novartis introduced Telbivudine, a revolutionary new antiviral drug for hepatitis B.

Challenge to India's patent laws

In 2006, Novartis launched a court case against India seeking to prohibit the country from developing affordable diabetes and other diseases who are too poor to pay for them."^[7] The high court also claimed to have no jurisdiction on whether Indian Patent law complied with WTO patent guidelines.

In the months leading up to the hearing, over half a million people wrote to the CEO of Novartis expressing their opposition to the suit. Novartis has decided not to appeal the ruling.^[8]

References